Disclaimer: This information is intended for educational purposes and should not be considered medical advice. It is designed to supplement, not replace, the judgment of healthcare professionals. Clinical decisions must always be made by a qualified practitioner based on the individual patient's condition, available evidence, and current clinical guidelines. Dosage information, specific values, and treatment protocols may vary and should be verified with current prescribing information and institutional policies.

Critical Illness Myopathy

Overview

• Definition: Critical illness myopathy (CIM) is an acute, generalized muscle weakness that develops in critically ill patients, particularly those with sepsis, multiple organ dysfunction syndrome (MODS), prolonged mechanical ventilation, and exposure to corticosteroids and neuromuscular blocking agents (NMBAs). It is characterized by severe muscle weakness, often disproportionate to the patient's underlying illness severity, and primarily affects skeletal muscles, including respiratory muscles.
• Epidemiology: CIM, often co-occurring with Critical Illness Polyneuropathy (CIP), is collectively known as Critical Illness Neuromyopathy (CIN). The exact incidence of isolated CIM is challenging to determine due to frequent co-existence with CIP.
  • Prevalence: Reported in 50-70% of patients with severe sepsis or MODS on mechanical ventilation.
  • Risk: Increases significantly with the duration of mechanical ventilation; nearly all patients ventilated for >2 weeks develop some degree of critical illness weakness.
  • Demographics: Affects all age groups, but risk increases with age and pre-existing comorbidities.
• Classification:
  • Acute Myopathy of Intensive Care (AMIC): A broader term often used interchangeably with CIM.
  • Specific subtypes: Based on electrophysiological and pathological findings, though often not distinct clinically:
    • Thick filament myopathy: Predominant loss of myosin (thick filament) in muscle biopsy, the most common pathological finding.
    • Necrotizing myopathy: Presence of muscle fiber necrosis and regeneration. Less common.
    • Non-necrotizing myopathy: Without significant necrosis.

Pathophysiology

• Mechanism: CIM is a complex disorder involving multiple interacting factors leading to muscle dysfunction and atrophy.
  • Muscle Protein Catabolism: Systemic inflammation (e.g., in sepsis) leads to activation of proteolytic pathways (ubiquitin-proteasome system, calpain, caspase-3), resulting in rapid degradation of muscle proteins, particularly myosin thick filaments.
  • Mitochondrial Dysfunction: Impaired mitochondrial oxidative phosphorylation and reduced ATP production contribute to energy deficit in muscle cells.
  • Ion Channel Dysfunction: Alterations in sodium channel activity (reduced expression or function) in the sarcolemma lead to muscle inexcitability and reduced force generation, even with intact nerve stimulation.
  • Microcirculatory Disturbances: Impaired microvascular perfusion and oxygen delivery to muscle tissue.
  • Disuse Atrophy: Prolonged immobility significantly contributes to muscle wasting, exacerbating the effects of systemic inflammation.
  • Direct Myotoxic Effects: Certain medications, notably high-dose corticosteroids (especially when combined with NMBAs) and NMBAs themselves, can have direct detrimental effects on muscle structure and function.
• Risk Factors:
  • Sepsis and Septic Shock
  • Multiple Organ Dysfunction Syndrome (MODS)
  • Prolonged Mechanical Ventilation (>4-7 days)
  • Systemic Corticosteroid Use (especially high doses and prolonged use)
  • Neuromuscular Blocking Agents (NMBAs), particularly prolonged use or in combination with corticosteroids
  • Hyperglycemia (poor glycemic control)
  • Prolonged Immobility and Malnutrition
  • Renal and Hepatic Failure
  • Hypophosphatemia, Hypomagnesemia, Electrolyte disturbances
  • Severe Asthma (status asthmaticus) treated with corticosteroids and NMBAs
• Protective Factors:
  • Aggressive treatment of underlying critical illness (e.g., source control of infection in sepsis).
  • Avoidance of prolonged or high-dose corticosteroids and NMBAs where clinically feasible.
  • Tight but not overly aggressive glycemic control (target blood glucose 140-180 mg/dL as per SCCM guidelines). Avoidance of hypoglycemia.
  • Early and aggressive physical rehabilitation and mobilization, even in intubated patients.
  • Adequate nutritional support.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Symmetrical, flaccid weakness of all four limbs, including proximal and distal muscles.
  • Difficulty weaning from mechanical ventilation, often out of proportion to pulmonary pathology.
  • Reduced or absent deep tendon reflexes (DTRs), though sensation is typically preserved (differentiates from CIP where sensation is also impaired).
• Early Signs:
  • Protracted weaning from mechanical ventilation.
  • Subtle limb weakness or failure to follow commands consistently.
  • Reduced spontaneous movements.
• Advanced Signs:
  • Quadriparesis or quadriplegia.
  • Profound muscle atrophy, visible as muscle wasting.
  • Complete absence of DTRs.
  • Difficulty with cough and swallowing, potentially affecting bulbar muscles (though less common than limb/respiratory muscle involvement).
• Atypical Presentations:
  • Unilateral or asymmetric weakness (rare, usually indicates an alternative diagnosis).
  • Predominant facial or bulbar weakness without significant limb involvement (very rare).

Physical Examination

• Inspection:
  • Generalized muscle wasting (atrophy), especially in prolonged cases.
  • Absence of spontaneous movement or flaccid paralysis.
  • May observe paradoxical breathing if diaphragmatic weakness is severe.
• Palpation:
  • Muscles may feel normal in tone initially, but manual muscle testing reveals profound weakness.
  • No tenderness or fasciculations typically.
• Special Tests:
  • Manual Muscle Testing (MMT): If patient is cooperative, reveals symmetrical weakness, often graded 0-2/5. Difficult to assess in sedated or uncooperative patients.
  • Assessment of Diaphragmatic Strength: Negative inspiratory force (NIF/MIP) <20 cm H2O or vital capacity (VC) <10-15 mL/kg suggests significant respiratory muscle weakness.
  • Deep Tendon Reflexes: Hypoactive or absent.
  • Sensory Examination: Typically normal, which helps differentiate CIM from CIP.
  • Cranial Nerves: Usually normal, though severe cases may affect bulbar muscles (swallowing, phonation).

Diagnostic Approach

History Taking

• Key Questions:
  • Duration of critical illness, admission diagnosis.
  • Presence of sepsis, MODS, ARDS.
  • Length of mechanical ventilation.
  • Medication history: Specifically inquire about corticosteroids (dose, duration) and neuromuscular blocking agents (type, dose, duration).
  • Glycemic control during ICU stay (history of hyperglycemia or hypoglycemia).
  • Nutritional status.
  • Any pre-existing neurological or muscular conditions.
  • Patient's functional status prior to critical illness.
• Red Flags:
  • Unexpected failure to wean from mechanical ventilation despite resolving primary respiratory pathology.
  • New onset symmetrical flaccid weakness in a critically ill patient, particularly after prolonged ventilation or exposure to risk factors.
  • Lack of improvement in strength after resolution of acute illness.

Laboratory Tests

• First-Line:
  • Creatine Kinase (CK): Typically normal or only mildly elevated (<3-5 times upper limit of normal). Elevated CK >1000 U/L suggests rhabdomyolysis or other primary muscle disorder, making CIM less likely.
  • Electrolytes: Rule out hypokalemia, hypophosphatemia, hypomagnesemia as causes of weakness.
  • Thyroid function tests: Rule out thyroid myopathy.
  • Inflammatory markers (CRP, procalcitonin): Reflect underlying critical illness.
• Confirmatory:
  • Electromyography (EMG) and Nerve Conduction Studies (NCS): The most valuable diagnostic tool.
    • NCS: Normal motor nerve conduction velocities and amplitudes or mildly reduced compound muscle action potentials (CMAPs). Sensory NCS are typically normal. Differentiates from CIP (which shows reduced sensory nerve action potentials and motor amplitudes).
    • EMG: Myopathic changes such as short-duration, low-amplitude motor unit potentials (MUPs) and abundant spontaneous activity (fibrillation potentials, positive sharp waves) indicating muscle membrane instability and denervation due to severe muscle damage. Reduced insertional activity and absent MUPs on maximal effort can indicate muscle inexcitability.
  • Muscle Biopsy: Considered the gold standard but rarely performed clinically due to invasiveness. Shows specific pathological changes:
    • Selective loss of myosin (thick filaments) without loss of actin (thin filaments).
    • Preservation of Z-bands and mitochondria.
    • Minimal or no inflammatory infiltrates.
    • May show varying degrees of necrosis and regeneration in some cases.
• Monitoring:
  • No specific laboratory tests for monitoring CIM recovery.
  • Monitoring is focused on resolving underlying critical illness and assessing functional improvement through serial physical examinations and rehabilitation assessments.

Imaging

• Recommended: No specific imaging studies are recommended for the diagnosis of CIM.
• Advanced:
  • MRI of Muscles: Rarely used, but can show diffuse muscle edema in the acute phase and muscle atrophy in chronic phases. Not diagnostic for CIM, mostly to rule out other conditions.

Management

Acute Management

• Immediate:
  • Supportive care: Ensure adequate ventilation and hemodynamic stability.
  • Identify and aggressively treat the underlying critical illness (e.g., source control for sepsis, appropriate antibiotics).
• Stabilization:
  • Optimize Glycemic Control: Maintain blood glucose levels between 140-180 mg/dL. Avoid hypoglycemia, which can worsen outcomes.
  • Minimize Sedation: Titrate sedation to the lowest effective dose to allow for early assessment of neurological status and facilitate patient participation in rehabilitation.
  • Limit Corticosteroids and NMBAs: Discontinue or reduce doses of corticosteroids and NMBAs as soon as clinically feasible. Avoid prolonged or concomitant use if possible.
  • Nutritional Support: Provide adequate protein and caloric intake to counteract muscle catabolism.
• Emergency:
  • Failure to wean from mechanical ventilation due to respiratory muscle weakness is a critical issue requiring ongoing ventilatory support and aggressive rehabilitation. CIM itself is not an immediate life-threatening emergency, but its consequence (respiratory failure) is.

Chronic Management

• Pharmacological:
  • There are no specific pharmacological treatments for CIM. Management is primarily supportive and rehabilitative.
• Non-pharmacological:
  • Early Mobilization and Physical Therapy: Crucial and cornerstone of management.
    • Initiate as soon as the patient is hemodynamically stable, often within 24-48 hours of ICU admission.
    • Progress from passive range of motion, to active-assisted, to active exercises, sitting up, standing, and ambulation.
    • Includes bed exercises, cycle ergometry, tilt-table, and ambulation when appropriate.
    • Evidence supports reduced ICU length of stay, ventilator days, and improved functional outcomes.
  • Occupational Therapy: Focuses on activities of daily living (ADLs) and functional independence.
  • Speech Therapy: If bulbar weakness affects swallowing or speech.
  • Nutritional Optimization: Maintain adequate protein intake to support muscle repair and growth during recovery.
• Monitoring:
  • Regular assessment of muscle strength (e.g., using Medical Research Council (MRC) sum score for strength).
  • Monitoring ventilator weaning progress.
  • Functional outcome measures (e.g., Functional Independence Measure (FIM), 6-minute walk test post-ICU).
  • Patient-reported quality of life assessments.

Treatment Algorithms

• First-Line:
  1. Aggressive management of the underlying critical illness (e.g., sepsis bundle adherence).
  2. Strict but appropriate glycemic control (140-180 mg/dL).
  3. Minimize/avoid prolonged corticosteroids and NMBAs.
  4. Early and progressive physical and occupational therapy.
  5. Adequate nutritional support.
• Second-Line:
  1. Multidisciplinary rehabilitation program (inpatient or outpatient) after ICU discharge.
  2. Addressing associated complications (e.g., pressure ulcers, DVT prophylaxis).
• Refractory Cases:
  1. Prolonged inpatient rehabilitation often required.
  2. Long-term home-based rehabilitation and assistive devices as needed.
  3. Psychological support for patients and families coping with prolonged disability.

Complications

• Common:
  • Prolonged mechanical ventilation and difficulty with ventilator weaning.
  • Significant and persistent muscle weakness and atrophy.
  • Reduced functional independence in activities of daily living (ADLs).
  • Increased length of ICU and hospital stay.
  • Pressure ulcers.
  • Venous thromboembolism.
• Serious:
  • Increased mortality (often due to prolonged critical illness and its complications, rather than CIM itself).
  • Increased risk of nosocomial infections due to prolonged hospitalization.
  • Pulmonary complications (e.g., pneumonia) due to impaired cough and respiratory muscle weakness.
• Long-term:
  • Persistent physical disability and reduced quality of life, even years after discharge.
  • Chronic pain and fatigue.
  • Post-intensive care syndrome (PICS), which includes physical, cognitive, and psychological impairments.
  • Increased healthcare utilization and rehospitalizations.

Prognosis

• Factors:
  • Severity and duration of underlying critical illness.
  • Presence and severity of concomitant CIP (CIN has worse prognosis than isolated CIM).
  • Age and pre-existing comorbidities.
  • Timeliness and intensity of rehabilitation.
  • Avoidance of ongoing risk factors.
• Survival: CIM itself is rarely a direct cause of death, but it is a marker of severe critical illness and is associated with increased in-hospital and long-term mortality (e.g., 6-month mortality rate 30-50% in severe cases).
• Quality of Life:
  • Many patients experience gradual improvement in muscle strength and functional status over several months to years.
  • Complete recovery is rare in severe cases. Most survivors experience some degree of persistent weakness, fatigue, and reduced exercise capacity.
  • Significant impact on return to work and pre-illness activities is common.

Prevention

• Primary: Aimed at preventing the initial occurrence of CIM.
  • Aggressive Management of Critical Illness: Prompt and effective treatment of sepsis, MODS, and other underlying conditions.
  • Optimal Glycemic Control: Maintain blood glucose levels between 140-180 mg/dL in critically ill patients, avoiding both hyperglycemia and hypoglycemia.
  • Minimize Sedation: Implement sedation vacations and light sedation protocols to facilitate early awakening and patient participation in rehabilitation.
  • Judicious Use of NMBAs: Use only when clinically necessary (e.g., severe ARDS, status epilepticus) and for the shortest possible duration. Monitor train-of-four (TOF) to ensure appropriate level of block.
  • Corticosteroid Stewardship: Use the lowest effective dose for the shortest duration necessary, especially avoiding concomitant use with NMBAs.
  • Early Mobilization and Rehabilitation: Initiate passive and active range of motion exercises, sitting, and ambulation as soon as the patient is hemodynamically stable. Protocols for early mobility are crucial.
• Secondary: Early detection and intervention in patients at high risk.
  • Regular neurological assessments in high-risk patients.
  • Consider EMG/NCS studies if weakness is suspected, especially if weaning difficulties are unexplained.
• Tertiary: Preventing complications and maximizing functional recovery once CIM has developed.
  • Intensive, multidisciplinary rehabilitation.
  • Nutritional support.
  • Management of complications like pressure ulcers, DVT.

Special Populations

• Pediatric:
  • CIM can occur in children, often in the context of severe sepsis, respiratory failure, or cardiac surgery.
  • Diagnosis can be more challenging due to developmental stage and difficulty with cooperation for MMT and EMG.
  • Principles of management (treating underlying illness, early mobilization) are similar.
  • Long-term developmental and functional outcomes require specific attention.
• Geriatric:
  • Elderly patients are at increased risk due to pre-existing sarcopenia, reduced physiological reserve, and higher rates of comorbidities.
  • Recovery may be slower and less complete compared to younger adults.
  • Emphasis on preventing deconditioning and falls during rehabilitation.
• Pregnancy:
  • CIM is rare in pregnancy itself. If a pregnant patient develops critical illness requiring ICU admission, the risk factors and management principles apply.
  • Consider fetal well-being if NMBAs or specific medications are used, though management of critical illness generally takes precedence.
• Comorbidities:
  • Diabetes Mellitus: Poor glycemic control is a significant risk factor. Tight control is paramount.
  • Chronic Kidney Disease/End-Stage Renal Disease: May alter drug metabolism (NMBAs, corticosteroids) and contribute to electrolyte imbalances, increasing CIM risk.
  • Chronic Obstructive Pulmonary Disease (COPD): Patients with COPD are prone to respiratory failure and often receive corticosteroids, increasing CIM risk. Weaning is often more challenging.

Clinical Pearls

• Diagnostic:
  • Always consider CIM in a critically ill patient who fails to wean from the ventilator without a clear pulmonary cause.
  • CK levels are typically normal or only mildly elevated, which helps differentiate CIM from other myopathies (e.g., rhabdomyolysis).
  • The combination of normal sensory nerve conduction studies with reduced motor nerve amplitudes and myopathic changes on EMG is highly suggestive of CIM and helps differentiate it from CIP.
  • Muscle biopsy is definitive but rarely needed in clinical practice.
• Treatment:
  • There is no "cure" or specific drug for CIM. The cornerstone of treatment is aggressive management of the underlying critical illness and early, sustained physical rehabilitation.
  • Prioritize mobilization and avoid prolonged immobility as soon as the patient is stable. Even small movements are beneficial.
• Pitfalls:
  • Attributing all weakness in a critically ill patient solely to sedation or residual effects of NMBAs, leading to delayed diagnosis and rehabilitation.
  • Overly aggressive glycemic control leading to hypoglycemia, which can exacerbate critical illness and potentially worsen CIM outcomes.
  • Failing to discontinue or reduce corticosteroids and NMBAs as soon as clinically appropriate.
  • Delaying rehabilitation until the patient is fully awake and cooperative; early, passive range of motion is crucial.

Recent Updates

• Guidelines:
  • Surviving Sepsis Campaign (SSC) Guidelines: Emphasize early mobility and rehabilitation in septic patients. The 2021 guidelines recommend early mobilization (strong recommendation, moderate quality of evidence) and suggest not routinely using NMBAs for more than 48 hours in adult patients with sepsis-induced ARDS (weak recommendation, low quality of evidence).
  • SCCM Clinical Practice Guidelines for Pain, Agitation, Sedation, Delirium, Immobility, and Sleep Disruption (PADIS): Strongly recommend early mobilization and physical/occupational therapy in critically ill adults.
• Evidence:
  • Increasing evidence supports the benefits of early progressive physical rehabilitation, leading to reduced ICU and hospital length of stay, fewer ventilator days, and improved functional outcomes at discharge and long-term.
  • Research continues on optimal glycemic targets and the precise mechanisms by which corticosteroids and NMBAs contribute to CIM.
• Controversies:
  • The optimal glycemic control target in critically ill patients, balancing the risks of hyperglycemia and hypoglycemia.
  • The exact role and optimal duration of NMBAs in specific conditions like severe ARDS, balancing benefit for oxygenation against risk of CIM.
  • The most effective specific rehabilitation protocols and timing for maximum benefit.

Key References

• Guidelines:
  • Evans L, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143.
  • Devlin JW, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873.
• Studies/Reviews:
  • Hermans G, et al. Critical illness polyneuropathy and myopathy. Crit Care Clin. 2015 Oct;31(4):689-708.
  • De Jonghe B, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002 Jun 19;288(22):2819-2827.
  • Stevens RD, et al. Critical illness neuromyopathy: a critical care concept. Arch Neurol. 2007 May;64(5):748-52.
  • Schweickert WD, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009 May 30;373(9678):1874-82.
  • Wollersheim T, et al. Critical illness myopathy and polyneuropathy: a long-term problem. Crit Care. 2018 Aug 30;22(1):210.